Multiparametric Monitoring of Early Response to Antiangiogenic Therapy: A Sequential Perfusion CT and PETCT Study in a Rabbit VX2 Tumor Model

Abstract EN

Objectives.

To perform dual analysis of tumor perfusion and glucose metabolism using perfusion CT and FDG-PET/CT for the purpose of monitoring the early response to bevacizumab therapy in rabbit VX2 tumor models and to assess added value of FDG-PET to perfusion CT.

Methods.

Twenty-four VX2 carcinoma tumors implanted in bilateral back muscles of 12 rabbits were evaluated.

Serial concurrent perfusion CT and FDG-PET/CT were performed before and 3, 7, and 14 days after bevacizumab therapy (treatment group) or saline infusion (control group).

Perfusion CT was analyzed to calculate blood flow (BF), blood volume (BV), and permeability surface area product (PS); FDG-PET was analyzed to calculate SUVmax, SUVmean, total lesion glycolysis (TLG), entropy, and homogeneity.

The flow-metabolic ratio (FMR) was also calculated and immunohistochemical analysis of microvessel density (MVD) was performed.

Results.

On day 14, BF and BV in the treatment group were significantly lower than in the control group.

There were no significant differences in all FDG-PET-derived parameters between both groups.

In the treatment group, FMR prominently decreased after therapy and was positively correlated with MVD.

Conclusions.

In VX2 tumors, FMR could provide further insight into the early antiangiogenic effect reflecting a mismatch in intratumor blood flow and metabolism.